Jeffrey Borenstein's Biography

Jeffrey Borenstein, Group Leader, Synthetic Biology; Director, Biomedical Engineering Center, Draper

Jeffrey T. Borenstein, PhD, is Group Leader for Synthetic Biology and Bio Instrumentation and Director, Biomedical Engineering Center at Draper in Cambridge, Massachusetts, where he leads programs in organ and disease models for drug discovery and safety testing, immuno-oncology platforms, organ assist devices and drug delivery systems. He has a Ph.D. in Physics and over twenty-five years of experience in the application of microsystems and microfabrication technologies toward medicine. Dr. Borenstein holds over 60 issued patents and 100 peer-reviewed journal articles and is a member of the National Academy of Inventors.

Modeling COVID-19 Infection Kinetics in a High Throughput Human Primary Epithelial Airway Organ-on-Chip

Tuesday, 22 March 2022 at 10:00

Add to Calendar ▼2022-03-22 10:00:002022-03-22 11:00:00Europe/LondonModeling COVID-19 Infection Kinetics in a High Throughput Human Primary Epithelial Airway Organ-on-ChipClinical Translation of Organoids and Organs-on-Chips 2022 in BostonBostonSELECTBIOenquiries@selectbiosciences.com

The COVID-19 pandemic has spurred unprecedented advances in vaccine development, but the identification and administration of efficacious therapeutics to treat critically ill patients has been less successful. A major limiting factor has been a lack of suitable preclinical tools for investigating mechanisms of COVID-19 infections, which are currently reliant upon various animal models and in vitro culture of immortalized cell lines. We report the first successful demonstration of robust and reproducible SARS-CoV-2 infection and viral replication in a human primary cell-based organ-on-chip, leveraging a recently developed tissue culture platform known as PREDICT96-ALI (Air-Liquid Interface.) These studies utilize human primary tracheobronchial epithelial cells derived from bronchoscopies performed on living donors, a capability that can ultimately lead to application of the technology to study patient-specific mechanisms of infection and therapeutic response, and the role of co-morbidities in these processes. This technology represents a powerful new pathway for modeling respiratory viral infections with high consequence pathogens, and an avenue for screening therapeutic candidates in a high throughput platform.

Add to Calendar ▼2022-03-21 00:00:002022-03-22 00:00:00Europe/LondonClinical Translation of Organoids and Organs-on-Chips 2022Clinical Translation of Organoids and Organs-on-Chips 2022 in BostonBostonSELECTBIOenquiries@selectbiosciences.com

Conference Sponsors